An open-label trial of aripiprazole in the treatment of aggression in male adolescents diagnosed with conduct disorder

Annals of Clinical Psychiatry

Volumn 23, Issue 4, 2011, Pages 270-276

  Kuperman, Samuel ^a   Calarge, Chadi ^a   Kolar, Anne ^a   Holman, Timothy ^b   Barnett, Mitchell ^b   Perry, Paul ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b TOURO UNIVERSITY CALIFORNIA   (United States)

Author keywords

Aggression; Aripiprazole; Conduct disorder

Indexed keywords

AMPHETAMINE; ARIPIPRAZOLE; CITALOPRAM; GUANFACINE; METHYLPHENIDATE; PROLACTIN; RISPERIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ACCOMMODATION; ADOLESCENT; AGGRESSION; AKINESIA; ANAMNESIS; ARTICLE; ATTENTION DEFICIT DISORDER; CHILDREN AGGRESSION SCALE PARENT VERSION; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONCENTRATION LOSS; CONDUCT DISORDER; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DREAMING; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMOTIONAL DISORDER; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HEADACHE; HEART PALPITATION; HUMAN; HYPERHIDROSIS; HYPERPIGMENTATION; HYPERSALIVATION; HYPOKINESIA; HYPOSALIVATION; MALE; MIGRAINE; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OVERT AGGRESSION SCALE MODIFIED; PATIENT ASSESSMENT; PHOTOSENSITIVITY; PHYSICAL EXAMINATION; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PRURITUS; PSYCHOMETRY; QUESTIONNAIRE; RATING SCALE; RIGIDITY; SEDATION; SEXUAL BEHAVIOR; SIDE EFFECT; SLEEP TIME; SOMNOLENCE; TACHYCARDIA; TENSION; TENSION HEADACHE; TREATMENT INDICATION; TREATMENT OUTCOME; VERBAL HOSTILITY; VITAL SIGN; WEIGHT GAIN; WEIGHT REDUCTION; DRUG EFFECT; PILOT STUDY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE;

ADOLESCENT; AGGRESSION; ANTIPSYCHOTIC AGENTS; CONDUCT DISORDER; HUMANS; MALE; PILOT PROJECTS; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; TREATMENT OUTCOME;

EID: 84858329093     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Birmaher B, Baker R, Kapur S, et al. Clozapine for the treatment of adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 1992;31: 160-164.
2. Gonzalez A, Michanie C. Clozapine for refractory psychosis. J Am Acad Child Adolesc Psychiatry. 1992;31:1169-1170.
3. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164:1050-1060. (Pubitemid 47121394)
4. Smulevich AB, Khanna S, Eerdekens M, et al. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol. 2005;15:75-84. (Pubitemid 39574402)
5. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314-321. (Pubitemid 34815353)
6. Scahill L, Leckman JF, Schultz RT, et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60:1130-1135. (Pubitemid 36418773)
7. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry. 2001;62:239-248. (Pubitemid 32428762)
8. Perry PJ, Alexander B, Liskow BI, et al. Psychotropic drug handbook. Baltimore, MD: Lippincott Williams and Wilkins; 2007.
9. Findling RL, Kauffman R, Sallee FR, et al. An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder. J Child Adolesc Psychopharmacol. 2009;19:431-439.
10. Diagnostic and statistical manual of mental disorders, 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
11. Data on file. Princeton, NJ: Bristol-Myers Squibb; 2003.
12. Kay SR, Wolkenfeld F, Murrill LM. Profiles of aggression among psychiatric patients. I. Nature and prevalence. J Nerv Ment Dis. 1988;176:539-546.
13. Halperin JM, McKay KE, Newcorn JH. Development, reliability, and validity of the Children's Aggression Scale-Parent Version. J Am Acad Child Adolesc Psychiatry. 2002;41:245-252. (Pubitemid 38338145)
14. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised (DHEW Publ No ADM 76-338). Rockville, MD: U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
15. Lane RD, Glazer WM, Hansen TE, et al. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis. 1985;173:353-357. (Pubitemid 15079180)
16. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
17. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676. (Pubitemid 19154942)
18. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100. (Pubitemid 17115352)
19. Barak Y, Aizenberg D. Switching to aripiprazole as a strategy for weight reduction: a meta-analysis in patients suffering from schizophrenia. J Obes. 2011. doi: 10.1155/2011/898013.
20. Seriwatanachai D, Charoenphandhu N, Suthiphongchai T, et al. Prolactin decreases the expression ratio of receptor activator of nuclear factor kappaB ligand/osteoprotegerin in human fetal osteoblast cells. Cell Biol Int. 2008;32:1126-1135.
21. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302:1765-1773.